Braidwell LP Boosts Stock Position in Harrow, Inc. (NASDAQ:HROW)

Braidwell LP increased its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 439,638 shares of the company's stock after acquiring an additional 142,450 shares during the quarter. Braidwell LP owned about 1.24% of Harrow worth $19,766,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Harrow in the third quarter worth about $29,000. nVerses Capital LLC bought a new stake in Harrow during the second quarter worth approximately $33,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock valued at $44,000 after purchasing an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after purchasing an additional 227 shares during the last quarter. Finally, Hills Bank & Trust Co purchased a new position in shares of Harrow in the 3rd quarter worth approximately $107,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Trading Down 1.3 %

Harrow stock traded down $0.56 during mid-day trading on Friday, hitting $41.91. The company's stock had a trading volume of 191,542 shares, compared to its average volume of 510,519. The company has a 50 day moving average of $47.61 and a 200-day moving average of $34.56. Harrow, Inc. has a one year low of $8.86 and a one year high of $59.23. The stock has a market cap of $1.49 billion, a PE ratio of -44.59 and a beta of 0.76. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Lake Street Capital raised their price target on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. B. Riley reissued a "buy" rating and issued a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th. Finally, Craig Hallum upped their price target on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a report on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.